TG Therapeutics leads Valneva on 12 of 14 measures

TG Therapeutics led Valneva on 12 of 14 measures in MarketBeat data republished by Baseball News Source on Oct. 10, including six current buy ratings versus one for Valneva.

The screen matters for investors because TG Therapeutics showed a 55.22% net margin and 58.6% institutional ownership on Oct. 10, compared with Valneva’s negative 110.33% margin and 11.4% institutional ownership.

MarketBeat data listed TG Therapeutics with two hold ratings and one sell rating, giving it a rating score of 2.56. Valneva had two sell ratings and no hold ratings, for a score of 1.67.

Valneva’s consensus price target was $9.30, implying 60.90% upside from the price used by MarketBeat. TG Therapeutics’ consensus target was $63.00, implying 13.78% upside.

TG Therapeutics also carried higher volatility, with a beta of 1.8 versus 1.53 for Valneva. Beta measures how much a stock tends to move against the S&P 500; TG’s figure implies 80% more volatility than the index, compared with 53% for Valneva.

The source listed TG Therapeutics with $616.29 million of gross revenue and $447.18 million of net income, compared with $197.56 million of gross revenue and a $130.33 million loss for Valneva. It did not specify the reporting period for those figures.

The companies have different business profiles. Valneva develops and sells vaccines, including IXIARO, DUKORAL and IXCHIQ. TG Therapeutics sells BRIUMVI for relapsing forms of multiple sclerosis and focuses on B-cell mediated diseases, conditions involving immune-system B cells.

Source: financial-data comparison article, Baseball News Source/MarketBeat, Oct. 10, 2026